Objective: Vasomotor symptoms (VMS) may be associated with an increased risk of cardiovascular disease. One candidate mechanism may involve alterations in physiological responses to stress. The current study therefore examined the relationship between self-reported VMS bother and cardiovascular, hemodynamic, neuroendocrine, and inflammatory responses to an acute psychosocial stress protocol.
V asomotor symptoms (VMS) are estimated to affect up to 70% of women in the early menopausal years 1 and are associated with impaired sleep, cognitive decline, and overall decreased quality of life. 2 Although findings are not entirely consistent, with one study finding VMS to be associated with a decreased risk of cardiovascular disease mortality, 3 several recent studies suggest that VMS frequency and/or severity may be positively associated with cardiovascular disease risk. In one 14-year longitudinal study of over 11,000 women aged 45 to 50 years, women who reported having VMS ''often'' had a two-fold increased risk of developing coronary heart disease (CHD) over the course of the study compared with women who reported no VMS. 4 Furthermore, the Women's Health Initiative Observational Study, involving approximately 60,000 postmenopausal women aged 50 to 79 years who were studied for an average of 9.7 years, 5 found that VMS, particularly late-onset VMS, were associated with an increased risk of major CHD, stroke, and total cardiovascular disease (hazard ratios ¼ 1.30-1.46). A third study followed over 10,000 Dutch and Swedish women aged 46 to 64 years for a mean of 10 years and found that night sweats, but not hot flashes, were associated with a moderately increased risk of CHD (hazard ratio ¼ 1.33). 6 VMS have also been associated with multiple cardiovascular disease precursors, including indices of subclinical cardiovascular disease. In an ancillary study of the Study of Women's Health Across the Nation including 492 women aged 45 to 58 years, hot flashes were associated with reduced flow-mediated dilation, increased coronary artery and aortic calcification, 7 and higher carotid intima media thickness. 8 A second cohort of 302 women participating in the Healthy Women Study, a longitudinal study initiated in 1983, found that women reporting a longer history of hot flashes exhibited increased aortic calcification. 9 Others have obtained similar findings, 10, 11 although null findings have also been reported. 12 In addition, VMS have been associated with other CVD risk factors, including increased body mass index, hypertension, elevated low-density lipoprotein cholesterol and triglycerides, 13 indicators of insulin resistance, 14 and diabetes. 15 The mechanisms linking VMS with a potentially increased cardiovascular risk profile are poorly understood. A small body of recent research investigating the physiology of hot flashes suggests that disturbances in the autonomic nervous system (ANS) and hypothalamic-pituitary-adrenal (HPA) axis may, however, represent a common link between VMS and cardiovascular disease. High-frequency heart rate variability, considered an index of cardiac vagal control, has been found to decrease significantly during hot flashes, [16] [17] [18] whereas lowfrequency heart rate variability, in part reflecting sympathetic activation, may be higher during hot flashes. 18, 19 Some evidence indicating that compounds increasing central sympathetic activation (eg, yohimbine) may provoke hot flashes whereas compounds reducing sympathetic activation (eg, clonidine) ameliorate them 20 also seem to implicate the ANS in the etiology of VMS. Although the link between VMS and the HPA axis is much less established, one study suggests that hot flashes are followed by a temporary increase in cortisol. 21 Indicators of altered ANS and HPA axis regulation are, in turn, associated with cardiovascular disease and its precursors. For example, exaggerated cardiovascular responses to acute mental stress 22, 23 have been shown to be associated with the development of hypertension, subclinical atherosclerosis, and cardiovascular events themselves. 14, 15 Although less well studied, some evidence also suggests that cortisol responses to acute mental stress are associated with coronary artery calcification. 24 Repeated exposure to elevated cortisol levels may also, over time, render individuals resistant to the anti-inflammatory effects of glucocorticoids, resulting in overall increased inflammation, 25 which is itself a risk factor for cardiovascular disease. 26 In addition, the relative contribution that the myocardium versus the vasculature makes to blood pressure (BP) levels, which is regulated by the ANS and sympathoadrenal medullary system, has been shown to be associated with CVD development. 27 More specifically, a hemodynamic stress profile characterized by less cardiac output and greater relative vasoconstriction has been observed in groups at increased risk for CVD. [28] [29] [30] [31] Thus, to the extent that ANS and HPA axis disturbances are positively associated with both VMS and CVD risk, such disturbances may represent a common link between VMS and CVD.
The current study examined the relationship between selfreported VMS and cardiovascular, hemodynamic, endocrine, and inflammatory responses at rest and during a well-validated acute mental stress task, the Trier Social Stress Test (TSST) in peri-and early postmenopausal women. This work may shed light on potential stress-responsive cardiovascular and neuroendocrine mechanisms linking VMS and CVD.
METHODS

Study overview
The current article describes the results of a cross-sectional analysis of the prerandomization data collected as part of the Perimenopausal Estrogen Replacement Therapy Study, a 12-month placebo-controlled randomized trial evaluating the mood and cardiovascular benefits of transdermal estradiol in perimenopausal and early postmenopausal women.
Participants first underwent an enrollment visit during which their study eligibility was assessed and informed written consent was obtained. At this time, participants completed questionnaires pertaining to their demographic characteristics, medical history, and current menopausal symptoms. One month after the enrollment session, those women who were determined to be eligible for the randomized controlled trial completed the first laboratory stress testing session, which included the TSST, during which multiple measures of cardiovascular and endocrine reactivity were assessed. Participants were subsequently randomized to receive transdermal estradiol (0.1 mg) and micronized progesterone pills (200 mg/d) or a placebo patch and placebo pills. The data included in this report, however, involves only the measures collected prerandomization.
Participants
One hundred eighty-six participants included in this article (Table 1 for participant characteristics) were recruited from the community to participate in the Perimenopausal Estrogen Replacement Therapy Study. Women were recruited who were aged 45 to 60 years, medically healthy, and perimenopausal or early postmenopausal according to the Stages of Reproductive Aging Workshop (STRAWþ10) criteria (early perimenopause, defined as menstrual cycle length 7þ days longer than usual in combination with hot flashes; late perimenopause, defined as !2 skipped cycles and an interval of amenorrhea !60 days but within 1 year of the last menstrual period; and early postmenopause defined as an interval of amenorrhea between 1 and 2 years). Women who had their uterus removed (!1 ovary retained) for whom menstrual bleeding patterns could not be assessed were included in the study if (1) they were experiencing VMS and their baseline estradiol levels were above the postmenopausal concentrations (>40 pg/mL) (n ¼ 17) or (2) they were not experiencing VMS but had baseline estradiol >40 pg/mL and baseline FSH levels >14 IU/L (n ¼ 4) (a cutoff of two standard deviations above the mean level obtained from a sample of premenopausal women, consistent with STRAW guidelines). 32 Exclusion criteria included the following: current psychiatric diagnosis of major depressive disorder or any other current psychiatric diagnosis with severity greater than mild, a Center for Epidemiological Studies Depression Scale score >16, a history of severe substance use within the past 10 years, GORDON ET AL a history of suicide attempts, use of psychotropic medication, hormonal preparations, or herbal compounds indicated for menopausal symptoms (eg, Black Cohosh) or mood (eg, St. John's Wort), use of statins or antihypertensive agents other than diuretics, regular over-the-counter medication use (eg, nonsteroidal anti-inflammatory agents), BP > 160/90 mm Hg, or any history of CVD. Multiple exclusion criteria aimed at minimizing the risk related to hormone therapy also applied and included the following: smoking more than 10 cigarettes/ d, endometrial hyperplasia, abnormal uterine anatomy, history of thrombophlebitis or thromboembolic disorders, history of estrogen-dependent neoplasias, and body mass index above 35. To be eligible for the study, women also must have had a normal mammogram within 1 year of study enrollment. The study protocol was approved by the UNC Chapel Hill Institutional Review Board. All participants provided informed, written consent before participating and received up to $1,525 in compensation for participating in the full 12-month randomized controlled trial.
Measures
VMS
VMS were measured during the enrollment session using the Greene Climacteric Scale (GCS), a self-report form that asks participants to rate the extent to which they are currently bothered by 21 menopausal symptoms on a 4-point scale from ''not at all'' to ''extremely''; two of these items included ''hot flushes'' and ''sweating at night,'' which were used to respectively assess hot flashes and night sweats in the current study.
Potential confounders
All potential confounding variables were assessed at the enrollment session. ''Race'' was assessed by self-report and included the following possible categories from which the participant could choose: White, African American, Native Hawaiian or Pacific Islander, Native American, Alaska Native, Black of Caribbean, Cuban, European or other descent, and Asian. Body mass index was calculated using researcher-assessed height and weight measurements. Light, moderate, and vigorous physical activity were assessed using the International Physical Activity Questionnaire (IPAQ) short form, 33 which provides examples of commonly performed activities at all intensities of physical activity and collects information on the duration (time spent) and frequency (number of days) engaged in activities lasting longer than 10 minutes over the course of the week to calculate the amount of Metabolic Equivalents (METs)-minutes associated with each physical activity level of intensity. To assess smoking, participants completed a questionnaire asking ''do you smoke?'' and ''if yes, approximately, how many cigarettes do you smoke in a day?'' Categories included 5 or less, 6 to 10, 11 to 15, 16 to 20, 20 or more. Average number of hours of sleep per night, assessed using one item from an abbreviated version of the St. Mary's Hospital Sleep Questionnaire (SMHSQ), 34 was used as an indicator of sleep. Average number of self-reported cups of caffeinated beverages consumed per day was used as an index of caffeine intake. Average number of self-reported alcoholic beverages consumed per week provided an index of alcohol intake. Menopause status was categorized as postmenopausal or perimenopausal based upon self-reported menstrual cycle information. Postmenopausal status required at least 1 year of amenorrhea. All other participants were classified as perimenopausal, including hysterectomized women meeting the estradiol and/or FSH study eligibility criteria. Psychological symptoms were assessed using the psychological subscale of the GCS, which consists of 11 items-five relating to depression and six relating to anxiety.
Laboratory testing
The sequence of laboratory events were as follows: (1) instrumentation and intravenous set-up, (2) recovery from venipuncture (20 min), (3) baseline (10 min quiet rest), (4) TSST (15 min), (5) recovery (60 min). These events are described below.
All laboratory sessions began at 1:00 PM. Upon arrival, participants were instrumented with a BP cuff and an electrocardiogram for later monitoring of cardiovascular stress reactivity. A catheter was then placed into a forearm vein, to be used for blood draws using a nonheparinized, multistopcock system allowing for blood samples to be taken at precise time intervals throughout testing. A curtain was drawn to prevent the participant from viewing the catheter and the blood draws during the stress protocol. Thirty minutes of quiet rest followed the i.v. setup, the first 20 minutes being recovery from venipuncture and 21 to 30 minutes constituting baseline. Blood pressure and heart rate were taken at minutes 21, 23, 25, 27, and 29 and averaged to yield a mean baseline value. Blood was sampled at minute 30 for baseline cortisol, IL-6, epinephrine, norepinephrine, and estradiol concentrations.
TSST
The TSST, which has been shown to induce a reliable stress response, 35 involved four components: (1) pretask instructions (1 min) during which participants were introduced to the committee who later listened to their job talk and were given instructions for the mental arithmetic task; (2) speech preparation period (5 min) during which time participants prepared a job talk for which they were to assume the role of a job candidate for their ''ideal job'' while the selection committee stood in the room; (3) job speech (5 min immediately after the preparation period), during which the participant delivered her job talk aimed at persuading the committee that she is the perfect candidate. If the participant ended her talk before 5 minutes, the selection committee questioned the participant in a systematic fashion to ensure the participant would speak the entire 5 minutes. (4) Serial subtraction task, which involved subtracting a one-digit number from a four-digit number as fast and as accurately as possible for 5 minutes. For each mistake, the participant was instructed by a member of the selection committee to restart from the beginning. Participants were video-recorded throughout their performance. After the arithmetic task, participants were asked to rate on a scale from 0 to 10 the extent to which the job speech and the arithmetic task caused them anxiety, fear, anger/ hostility, and feelings of rejection. Using a similar scale, participants also rated how difficult the tasks were and how much effort they exerted in completing the tasks. Participants then sat quietly while watching a 60-minute travel documentary specifically chosen to include only mundane footage.
BP and heart rate were obtained at minutes 1, 3, and 5 of the speech preparation period, the job speech, and the arithmetic task, and at minutes 2, 4, 8, 10, 13, 16, 20, 25, 30, 40, 45, 56 , and 60 of the recovery period. These measures were then averaged to obtain a mean preparation, speech task, arithmetic task, and recovery value for each measure. Plasma epinephrine and norepinephrine were sampled at minute 1 of the job speech and at minute 1 of the arithmetic task because catecholamines peak within the first 2 minutes of mental stress. 36 Plasma cortisol and IL-6 were measured 10, 20, 30, 45, and 60 minutes after the end of the TSST to capture the delayed HPA and IL-6 responses to mental stress.
37-39
Physiological recording procedures
The SunTech Exercise BP monitor, Model 4240 (SunTech Medical Instruments, Inc, Raleigh, NC) provided BP measurements during baseline and mental stress testing. Five standard stethoscopic and automated BP measurements were taken simultaneously to ensure correct microphone placement and cuff position.
Impedance cardiography was used to noninvasively monitor cardiovascular activity, 40 including cardiac output, stroke volume, total peripheral resistance, and heart rate. A custom-designed impedance cardiograph (HIC-100 Bioimpedance Technology, Inc, Model 100, Chapel Hill, NC) was used in conjunction with a tetrapolar band electrode configuration to record impedance dZ/dt and Z 0 signals. Impedance and electrocardiogram signals were processed online by specialized computer software (BIT, Chapel Hill, NC) with subsequent manual editing to improve accuracy. For each minute of interest, a 30-second continuous sample of waveforms (obtained concurrently with BP) was processed to generate an ensemble-averaged cardiac cycle, from which stroke volume was determined using the Kubicek et al (1966) 41 equation and heart rate was determined using the mean interbeat interval. Cardiac output and total peripheral resistance for these same minutes were then calculated using standard formulae. 40 Cardiac output, stroke volume, and total peripheral resistance were adjusted for individual variations in body size by using body surface areas to derive cardiac index, stroke volume index, and vascular resistance index.
Hormone and neuroendocrine assays
Plasma cortisol levels were measured using a competitive coated tube radioimmunoassay kit and protocol, commercially available from MP Biomedicals, Orangeburg, NY. The sensitivity of the assay is 0.07 ug/dL with intra-and interassay variations of 4.7% and 7.6%, respectively.
Plasma IL-6 levels were determined using a high-sensitivity ELISA assay kit and protocol from R&D Systems, Minneapolis, MN. The sensitivity of the assay is 0.039 pg/ mL with a standard range of 0.156 to 10 pg/mL with intra-and interassay variations of 7.8% and 7.2%, respectively.
Plasma epinephrine and norepinephrine concentrations were determined (Labcorp) using an isocratic high performance liquid chromatography (HPLC) system and an electrochemical detector from Chromsystems, Germany. The lower limit of quantification for both compounds is 15 ng/L. Intraassay and the intra-assay and interday coefficients of variation are less than 11% and less than 13%, respectively.
Statistical analyses
Sensitivity analyses were used to identify extreme outliers before data analysis, defined as values 3 or more interquartile ranges below the first quartile or above the third quartile (SAS Institute Inc, 2011). This resulted in IL-6 data being removed for three participants, cardiac index data being removed for one participant, stroke volume index being removed for one participant, norepinephrine data being removed for one participant, and epinephrine data being removed for four participants. Although BP and heart rate were normally distributed, cardiac index, vascular resistance index, stroke volume index, epinephrine, norepinephrine, cortisol, and IL-6 were log-transformed due to non-normality. Means included in tables and figures have been back-transformed.
For each cardiovascular or neuroendocrine measure, t tests comparing levels during the baseline period versus during the speech task were used to confirm a significant effect of the TSST on cardiovascular and neuroendocrine measures.
Univariate regression analyses, using a P value of 0.05 as the criterion for statistical significance, assessed whether hot flashes and night sweats were each associated with a number of potential confounding variables that have been shown to influence responses to mental stress. Those variables found to be significantly associated with VMS were identified as
For each physiologic-dependent measure, a multivariate repeated measures general linear regression model, with stress testing task (baseline, preparation, speech, arithmetic, recovery) as the repeated measure, was used to examine the effects of hot flashes and night sweats (examined separately) on stress physiology. The Greenhouse-Geisser correction was used whenever appropriate to correct for sphericity.
RESULTS
Participant characteristics
As reflected in Table 1 , the participants were of average socioeconomic status and reflected the racial demographics of our region (73% White, 22% African American, and 5% other). The extent to which the participants reported being bothered by hot flashes was as follows: 33.9% endorsed ''not at all,'' 36.0% endorsed ''a little,'' 25.3% endorsed ''quite a bit,'' and 4.8% endorsed ''extremely.'' A similar distribution was seen for night sweats: 37.8% endorsed ''not at all,'' 34.6% endorsed ''a little,'' 22.2% endorsed ''quite a bit,'' and 5.4% endorsed ''extremely.''
Overall efficacy of the stress protocol
Systolic BP, diastolic BP, and heart rate all significantly increased in response to the mental stressors (t(179) ¼ 32.8, 30.0, and 23.9; P < 0.0001, respectively) as did cardiac index (t(179) ¼ 19.7, P < 0.0001), stroke volume index (t(180) ¼ 2.5, P ¼ 0.013), epinephrine (t(137) ¼ 9.6, P < 0.0001), cortisol (t(169) ¼ 8.7, P < 0.0001), and IL-6 (t(139) ¼ 2.5, P ¼ 0.013). Vascular resistance index decreased (t(179) ¼ À8.7, P < 0.0001), although no effect of the mental stress was seen for plasma norepinephrine (P ¼ 0.098) ( Table 2) .
Vasomotor symptoms and potential confounding variables
Neither hot flashes nor night sweats were significantly associated with race (whites vs other, blacks vs other) (Ps ¼ 0.150, 0. postmenopausal status, and psychological GCS subscale score were identified as appropriate covariates for multivariate analyses involving hot flashes and vigorous physical activity, psychological GCS subscale score, whereas average number of hours of sleep were identified as appropriate covariates for multivariate analyses involving night sweats.
Hot flashes and physiologic responses to stress
Multivariate analyses examining the effect of hot flashes on stress physiology included average weekly METs of vigorous physical activity, psychological GCS subscale score, and menopausal status as covariates.
Blood pressure and heart rate
Hot flashes were not associated with systolic BP (P ¼ 0.715), diastolic BP (P ¼ 0.916) or heart rate (P ¼ 0.971), nor did hot flashes interact with task to influence these variables (Ps ¼ 0.303-0.610).
Hemodynamic measures
Hot flashes were associated with lower overall cardiac index (F(1, 170) ¼ 7.66, P ¼ 0.006) (Fig. 1 ) and stroke volume index (F(1, 170) ¼ 7.35, P ¼ 0.007) and higher overall vascular resistance index (F(1, 169) ¼ 5.72, P ¼ 0.018) (Fig. 2) . Hot flashes, however, did not interact with task to predict cardiac index, stroke volume index, or vascular resistance index levels (Ps ¼ 0.499, 0.528, and 0.759, respectively).
Norepinephrine
Hot flashes tended to be associated with overall higher norepinephrine (F(1, 130) ¼ 2.80, P ¼ 0.097) (Fig. 3) and tended to interact with task to predict norepinephrine levels (F(2, 260) ¼ 2.51, P ¼ 0.097) such that the effect of hot flashes on norepinephrine was only significant at baseline (P ¼ 0.025).
Epinephrine
Hot flashes were not associated with overall epinephrine (P ¼ 0.168) and did not interact with task to predict epinephrine levels (P ¼ 0.993).
Cortisol
Hot flashes tended to be associated with overall elevated cortisol levels (F(1, 157) ¼ 2.80, P ¼ 0.097) ( Table 3) but symptoms did not interact with task to predict cortisol levels (P ¼ 0.395).
IL-6
Hot flashes were associated with overall higher IL-6 (F(1, 128) ¼ 4.71, P ¼ 0.032) and interacted with task to predict IL-6 levels (F(1, 640) ¼ 4.21, P ¼ 0.002) such that the effect of hot flashes on IL-6 was significant at all time points except 45 and 60 minutes after the end of the TSST.
Night sweat severity and physiologic responses to stress
Multivariate analyses examining the effect of night sweats on stress reactivity included average number of hours of sleep per night and average weekly METs of vigorous physical activity and psychological GCS subscale score as covariates.
Blood pressure and heart rate
Night sweats were not associated with systolic BP (P ¼ 0.900), diastolic BP (P ¼ 0.510), or heart rate (P ¼ 0.605), nor did night sweats interact with task to influence these variables (Ps ¼ 0.373-0.608).
Hemodynamic measures
Night sweats were not associated with overall cardiac index or vascular resistance index (Ps ¼ 0.125, 0.123), and did not interact with task to predict cardiac index or vascular resistance index levels (Ps ¼ 0.736 and 0.967, respectively). No main effect of night sweats or any symptom-by-task 
Norepinephrine
Night sweats were not associated with overall norepinephrine (P ¼ 0.125) and did not interact with task to predict norepinephrine levels (P ¼ 0.533).
Epinephrine
Night sweats were not associated with overall epinephrine levels (P ¼ 0.142) and did not interact with task to predict epinephrine levels (P ¼ 0.845).
Cortisol
Night sweats were positively associated with cortisol levels overall (F(1, 153) ¼ 4.55, P ¼ 0.035) but did not interact with task to predict cortisol levels (P ¼ 0.289) (Fig. 4) .
IL-6
Night sweats tended to be associated with higher overall IL-6 levels (F(1, 124) ¼ 3.36, P ¼ 0.069) ( Table 3 ) but symptoms did not interact with task to predict IL-6 levels (P ¼ 0.110).
DISCUSSION
The current study investigated the relationship between self-reported VMS and physiological responses to an acute mental stressor battery. Results indicated that although VMS bother was not associated with alterations in stress reactivity, per se, self-reported hot flash bother was associated with lower overall cardiac index, lower overall stroke volume index, higher overall vascular resistance index, and higher overall IL-6 levels. Hot flash bother also tended to be associated with elevated baseline norepinephrine levels and higher overall cortisol. Night sweat bother, on the other hand, was only associated with higher overall cortisol levels and tended to be associated with higher overall IL-6 levels.
Plasma norepinephrine is primarily reflective of sympathetic neural activity, 42 whereas plasma epinephrine primarily reflects sympathoadrenal medullary activity; the current results, therefore, suggest that hot flash bother tends to be associated with elevated sympathetic neural activation but unaltered sympathoadrenal activation. An increase in central versus peripheral ANS activity may help explain why hot flashes were found to be associated with overall lower cardiac index, lower stroke volume index, and higher vascular resistance index. Plasma norepinephrine, which was higher overall in women reporting being more bothered by hot flashes, binds to b-adrenergic receptors on the heart, leading to increased cardiac output; in the vasculature, however, norepinephrine preferentially binds to a-adrenergic receptors, stimulation of which promotes vasoconstriction and increased vascular resistance. 43 Thus, a relative profile of increased vasoconstriction coupled with decreased myocardial activity is consistent with the relatively elevated plasma norepinephrine levels observed in women with more bothersome hot flashes. Our finding that self-reported hot flash bother, and, to a lesser extent, night sweat bother, is associated with elevated norepinephrine levels and is consistent with the observation that 3-methoxy-4-hydroxyphenylglcol, the main metabolite of plasma norepinephrine, is significantly higher in postmenopausal women experiencing VMS compared with asymptomatic women. 44 It is also in line with several studies implicating the ANS in the pathophysiology of hot flashes themselves. For example, as mentioned above, there is some evidence that increasing central sympathetic output with the use of yohimbine (which blocks the a2 autoreceptor on noradrenergic neurons and therefore increases norepinephrine output) provokes hot flashes while inhibiting central sympathetic activation with clonidine (an a2 autoreceptor agonist) reduces hot flashes. 20 Studies examining changes in heart rate variability with hot flash onset also suggest that hot flashes are associated with a shift in sympathovagal balance toward sympathetic predominance. [16] [17] [18] [19] To our knowledge, the current study is, however, the first to examine VMS in relation to indices of both sympathetic and sympathoadrenal medullary activation within the context of acute mental stress.
It is unclear why daytime hot flashes, but not night sweats, were associated with elevations in central sympathetic activity and hemodynamic alterations in cardiac output, stroke volume, and total peripheral resistance. These differences will need to be replicated using objective measures of hot flash and night sweat severity to ensure that the observed differences are not driven by less accurate reporting of night sweats relative to daytime hot flashes.
Although the results of this cross-sectional study should be considered preliminary, if confirmed in future research, the association of hot flashes with higher vascular resistance index, lower cardiac index, and lower stroke volume index may have important implications for our understanding of the relationship between VMS and CVD. Reduced myocardial activity and greater vasoconstriction in the context of stress are seen in individuals at higher risk for CVD relative to their lower risk counterparts; for example, in postmenopausal relative to premenopausal women, 45 in men relative to premenopausal women, 46, 47 and in blacks relative to whites. 48, 49 Perhaps more relevant to the current study's finding that hot flash severity was associated with overall hemodynamic tone rather than hemodynamic stress reactivity, per se, blacks have also been shown to have lower resting cardiac index and higher resting vascular resistance index compared with whites, 30 and aging (the primary predictor of cardiovascular disease) is associated with increases in resting vascular resistance index and decreases in resting cardiac index. 50 Moreover, greater vascular resistance index tone may contribute to left ventricular hypertrophy, 51 an independent predictor of cardiovascular disease morbidity/mortality. 52, 53 Multivariate analyses also suggested a positive association between night sweats and, to a lesser extent, hot flashes, and circulating cortisol levels. These results are consistent with one study linking self-reported VMS bother to increased 24-hour urinary cortisol output 54 as well as the observation that cortisol levels increase after an objectively assessed hot flash. 21 Given that HPA axis hyperarousal is associated with multiple cardiovascular disease risk factors, including abdominal obesity, hypertension, insulin resistance, and diabetes, 55, 56 a positive association between VMS and circulating cortisol levels could have important health implications for peri-and postmenopausal women.
Hot flash, and to a lesser extent, night sweat bother were also associated with elevated IL-6 levels in multivariate analyses. Although few studies have examined the association between VMS and inflammation, one study did observe elevated IL-6 and IL-8 levels among women reporting more severe hot flashes. 57 The Study of Women's Health Across the Nation did not, however, find a relationship between VMS frequency and C-reactive protein 58 when adjusting for body mass index, the levels of which would be expected to rise in response to elevated levels of IL-6-further research is therefore needed to settle these inconsistencies. Although the mechanisms by which VMS would be associated with greater inflammation are unknown, one possibility may be that prolonged/repeated exposure to elevated cortisol, both in the context of hot flashes themselves 21 and during stress (as suggested by the current findings), promotes a desensitization to cortisol's anti-inflammatory effects, a process that has been hypothesized to underlie the association between chronic stress and increased inflammation. 25 The current study results should be interpreted in light of several limitations, perhaps the most important of which is its use of self-reported VMS bother using two questionnaire items. Assessing objective VMS frequency using skin conductance or even a prospective diary would allow us to rule out the possibility that the HPA axis and autonomic and hemodynamic alterations observed in the current study are associated with a greater propensity to be bothered by VMS, rather than being associated with VMS themselves. A related second limitation is that we cannot rule out the possibility that some women reporting more bothersome VMS experienced a hot flash either before or during stress testing, which might have influenced some of the measures under investigation. Third, the cross-sectional nature of this study does not allow us to determine the direction of the relationship between VMS severity and the neuroendocrine and hemodynamic alterations observed. Longitudinal studies will clarify whether these physiologic alterations precede or are preceded by the development of VMS in menopause. Such research would provide some insight into whether the observed VMS-related hemodynamic, neuroendocrine, and immune/inflammatory alterations are etiologically related to VMS, result from repeated exposure to VMS, or are a by-product of some other process influencing VMS. Fourth, hemodynamic data estimated by impedance cardiography are validated for research purposes only 59 and are not intended to reflect clinical indices of cardiovascular function as determined by invasive catheter-based hemodynamic assessments. Hemodynamic data produced by impedance cardiography may also be less precise than catheter-based assessments. Finally, generalizability of the current study's findings may be limited by several aspects of the study design. First, the fact that the women were participants of a randomized clinical trial of hormone therapy disallowed the inclusion of women who may have been at greatest risk for menopausal symptoms for safety reasons (eg, women with obesity) and also likely resulted in a sample that was healthier than average perimenopausal women. Second, although our sample was racially diverse, there was less diversity in socioeconomic status, which could well influence the nature and frequency of psychosocial stressors that were proximate to the menopausal transition. Despite these limitations, the current study fills an important gap in the literature. Although two studies have examined whether mental stress induces VMS in the laboratory, 17, 60 to our knowledge, this is the first study to examine whether VMS bother is associated with altered physiologic responses to acute stress. Its comprehensive assessment of cardiovascular hemodynamic, catecholamine, HPA, and immune/inflammatory measures is also particularly unique. If confirmed in longitudinal and interventional studies, the current study's findings suggest potential mechanisms by which VMS may be associated with an increased risk of cardiovascular disease.
CONCLUSIONS
The current study suggests that self-reported VMS bother is associated with greater HPA and immune/inflammatory activation, both of which have been associated with an increased risk for cardiovascular disease and its precursors. Hot flashes are additionally associated with elevated baseline central sympathetic tone, and an impedance-derived hemodynamic profile characterized by lower cardiac output and stroke volume and greater vasoconstriction, which is also associated with an increased cardiovascular disease risk. Should the current study's results be replicated using a state of the art measure of VMS, they may have important implications for understanding the potential relationship between VMS and indices of cardiovascular disease risk and the physiology of VMS themselves.
